Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic variants (gBRCA1-2pv): a multicenter survey

G. Orsi1,2, M. Di Marco3,4, A. Cavaliere5, M. Niger6, S. Bozzarelli7, G. Giordano8,9, S. Noventa10, I. G. Rapposelli11, I. Garajova12, G. Tortora13,14, M. G. Rodriquenz15, A. Bittoni16, E. Penzo1,17, S. De Lorenzo3, U. Peretti1,2, C. Paratore18, M. Scartozi25, L. Forti26, M. M. Valente1,2, A. M. Militello1,2, S. Cascinu1,17, M. Milella5 & M. Reni1,2*

Background: Germline BRCA1-2 pathogenic variants (gBRCA1-2pv)-related pancreatic ductal adenocarcinoma (PDAC) showed increased sensitivity to DNA cross-linking agents. This study aimed at exploring safety profile, dose intensity, and activity of different chemotherapy regimens in this setting.

Patients and methods: gBRCA1-2pv PDAC patients of any age and clinical tumor stage who completed a first course of chemotherapy were eligible. A descriptive analysis of chemotherapy toxicity, dose intensity, response, and survival outcomes was performed.

Results: A total of 85 gBRCA1-2pv PDAC patients treated in 21 Italian centers between December 2008 and March 2021 were enrolled. Seventy-four patients were assessable for toxicity and dose intensity, 83 for outcome. Dose intensity was as follows: nab-paclitaxel 72%, gemcitabine 76% (AG); cisplatin 75%, nab-paclitaxel 73%, capecitabine 73%, and gemcitabine 65% (PAXG); fluorouracil 35%, irinotecan 58%, and oxaliplatin 64% (FOLFIRINOX). When compared with the literature, grade 3-4 neutropenia, thrombocytopenia, and diarrhea were increased with PAXG, and unmodified with AG and FOLFIRINOX. RECIST responses were numerically higher with the three- (81%) or four-drug (73%) platinum-containing regimens that outperformed AG (41%) and oxaliplatin-based doublets (56%). Carbohydrate antigen 19.9 (CA19.9) reduction >89% at nadir was reported in two-third of metastatic patients treated with triplets and quadruplets, as opposed to 33% and 45% of patients receiving oxaliplatin-based doublets or AG, respectively. All patients receiving AG experienced disease progression, with a median progression-free survival (mPFS) of 6.4 months, while patients treated with platinum-containing triplets or quadruplets had an mPFS >10.8 months. Albeit still immature, data on overall survival seemed to parallel those on PFS.

Conclusions: Our data, as opposed to figures expected from the literature, highlighted that platinum-based regimens provoked an increased toxicity on proliferating cells, when dose intensity was maintained, or an as-expected toxicity.

*Correspondence to: Dr M. Reni, Medical Oncology Department, Pancreas Translational and Clinical Research Center, IRCCS San Raffaele Scientific Institute, Via Olgettina 60, 20132 Milan, Italy. Tel: +39-02-26437644 E-mail: reni.michele@hsr.it (M. Reni).

2059-7029/© 2021 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology. This is an open access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Available online xxx
when dose intensity was reduced, while no change in toxicity and dose intensity was evident with AG. Furthermore, an apparently improved outcome of platinum-based triplets or quadruplets over other regimens was observed.

**Key words:** germline BRCA, pancreatic cancer, chemotherapy toxicity, chemotherapy dose intensity, chemotherapy activity

## INTRODUCTION

In the past decades, DNA damage repair systems have caught the attention of researchers as potential therapeutic targets in oncology. Of special interest is the homologous recombination (HR) system, which is responsible for DNA double-strand break repair and pivots on BRCA1 and BRCA2 proteins. Historically, inheritance of germline BRCA1 and/or BRCA2 pathogenic variants (gBRCA1-2pv) has been associated with increased risk of breast and/or ovarian cancer. In addition, it has been demonstrated that, as a result of their increased genomic instability due to defective HR system, BRCA1-2-deficient cancers show higher sensitivity to DNA damaging agents inducing double-strand breaks, such as cross-linking agents, especially platinum compounds, and alkylating agents. Poly (ADP-ribose) polymerase (PARP) inhibitors have further enriched the therapeutic armamentarium against these neoplasms.

More recently, a significant correlation between gBRCA1-2pv and the risk of developing other malignancies, including prostate and gastrointestinal cancers, especially pancreatic ductal adenocarcinoma (PDAC), has been highlighted. PDAC is a highly challenging neoplasm, still burdened with low survival rates, mainly due to late stage at diagnosis, early spread of micrometastatic disease, and poor response to cytotoxic agents, which represent the unique therapeutic option in most cases. For carriers of gBRCA2 pathogenic variants, the lifetime risk of developing PDAC is estimated between 5% and 10%, while gBRCA1 pathogenic variants are associated with a two to four times increased risk of PDAC. Overall, prevalence of these germline pathogenic variants varies from 5% to 9% in unselected PDAC populations to 15%-20% in familial PDAC. Despite the low quality of clinical evidence, many studies have confirmed that PDAC patients carrying gBRCA1-2pv could benefit from platinum-based treatments, that are, however, hampered by toxicity. Moreover, the PARP inhibitor olaparib has been recommended for maintenance treatment of metastatic PDAC patients with gBRCA1-2pv, not progressing on first-line platinum-based chemotherapy, on the basis of the results of the randomized phase III POLO trial.

Despite an increasing interest in the efficacy of specific chemotherapy and chemo-free strategies in gBRCA1-2-mutated tumors, few studies have investigated chemotherapy toxicity in this subset of patients, often leading to inconsistent results. Indeed, it might be hypothesized that the defective allele that germline BRCA1-2pv carriers harbor in all healthy cells could lead to a partial impairment of the BRCA-related HR system and increased susceptibility to DNA damage also in non-neoplastic haploinsufficient cells, ultimately resulting in enhanced chemotherapy-related toxicity. Different and controversial data are available on chemotherapy toxicity in breast and ovarian cancer patients with gBRCA1-2pv, while no reports have addressed this topic in PDAC patients with gBRCA1-2pv.

For this reason, in this multicentric study we aimed at exploring the safety profile, alongside the activity, of different chemotherapy regimens in a cohort of chemonaive PDAC patients carrying gBRCA1-2pv, in order to achieve a deeper understanding of this clinical open and unexplored issue.

## PATIENTS AND METHODS

### Study design and inclusion criteria

This retrospective multicenter study involved 21 Italian oncology departments and was based on clinical—pathological data retrieved from medical records and collected in an electronic database. Patients of any age with documented germline pathogenic variants of BRCA1-2 genes were eligible for this analysis if they had a pathologically confirmed diagnosis of PDAC, had received a first course of chemotherapy by the time of database lock (March 2021), irrespective of the type (adjuvant, primary/neoadjuvant, metastatic first line) and regimen, and had available data on treatment toxicity and/or outcome. All patients enrolled in the study provided a written informed consent for germline BRCA1-2 test, which included the authorization for the use of clinical—pathological and genomic data for scientific purposes, in full compliance with privacy policy.

Patients and tumor characteristics included type of germline BRCA pathogenic variant, age, ECOG Performance Status, clinical stage (AJCC/UICC TNM 8th Edition, 2017), T site, grading, and presence/absence of liver metastases at diagnosis. Concerning the first chemotherapy administered, we collected information on baseline value of carbohydrate antigen 19.9 (CA19.9), type of chemotherapy (adjuvant, neoadjuvant/primary, first line metastatic), regimen, number of cycles and duration (in weeks), dose intensity, toxicity, and outcome.

Treatment toxicity was evaluated considering the maximum grade of toxicity observed for each regimen and for each patient during the first chemotherapy, referring to the Common Terminology Criteria for Adverse Events 5.0 (CTCAE 5.0). Concurrently, analysis of the dose intensity of each drug was also performed and reported as the percentage of the ratio between the real weekly average dose and the ideal weekly average dose.

Outcome analyses based on RECIST version 1.1 and CA19.9 best response were performed for each first-line
metastatic or primary/neoadjuvant chemotherapy regimen subgroup including at least nine patients. The percentage of surgically resected patients among those treated with primary/neoadjuvant chemotherapy was also recorded. Overall survival (OS) was calculated from the date of chemotherapy start until the date of death or last follow-up visit for patients receiving first-line metastatic chemotherapy, while the date of surgery was the starting time-point for those receiving adjuvant chemotherapy. Progression-free survival (PFS) was calculated from the date of chemotherapy start until the date of documented disease progression or death in patients without disease progression or last follow-up visit for patients receiving first-line metastatic chemotherapy. Disease-free survival (DFS) was calculated for patients receiving adjuvant chemotherapy, starting from the date of surgery until the date of disease relapse or last follow-up visit.

**Statistical analysis**

All patients were followed up until death or the time of database lock (March 2021). The primary endpoint of the study was to perform a descriptive analysis of treatment toxicity in PDAC patients carrying gBRCA1-2p and compare the results with the safety profile of the different chemotherapy regimens reported in the literature. The secondary endpoints were the descriptive analysis of objective response rate, disease control rate, and survival outcomes, including PFS, DFS, and OS. For this reason, no statistical design or sample size calculation was performed.

**Patient consent**

Before testing, all patients signed an informed consensus statement that was revised and approved by a local ethics committee and allowed for genetic testing and data collection, analysis, and elaboration. Data were irreversibly anonymized before entering into the database.

**RESULTS**

**Patients and treatment characteristics**

The final analyses of this multicenter survey encompassed 85 PDAC patients with gBRCA1-2 pathogenic variants, who received at least a first course of chemotherapy in 21 Italian oncology departments, between December 2008 and March 2021, and for whom data on treatment toxicity and/or outcome were available. Specifically, data on chemotherapy toxicity were available for 74 of 85 patients, while treatment outcomes were assessable in 83 cases.

Patients and treatments characteristics are presented in Table 1. No relevant difference was detected between the general study population and the subsets of patients evaluable for toxicity (toxicity cohort) and for outcome (outcome cohort). Characteristics of the four largest first-line chemotherapy regimen subgroups (n ≥ 9), including the 53 metastatic patients who were assessed for outcome, are reported in Table 2.

**Treatment toxicity and dose intensity**

Treatment toxicity and dose intensity of the four most commonly used (n ≥ 9) chemotherapy regimens, including nab-paclitaxel plus gemcitabine (AG),; folinic acid, fluorouracil, irinotecan, and oxaliplatin (FOLFIRINOX),; modified FOLFIRINOX (mFOLFIRINOX); and cisplatin, nab-paclitaxel, capecitabine, and gemcitabine (PAXG),; are summarized in Tables 3 and 4, respectively. Grade 3-4 toxicities occurring in >10% of patients were neutropenia (39%) and anemia (11%) for AG; neutropenia (47%) for FOLFIRINOX; neutropenia (30%), anemia (20%), and fever (20%) for mFOLFIRINOX, and neutropenia (66%), diarrhea (25%), thrombocytopenia (17%), anemia (17%), fatigue (17%), and nausea (17%) for PAXG.

No peculiar toxicity has apparently emerged with other less commonly recommended chemotherapy regimens, such as gemcitabine, gemcitabine plus oxaliplatin (GEMOX), cisplatin, epirubicin, capecitabine, and gemcitabine (PEXG), folinic acid, fluorouracil, and oxaliplatin (FOLFOX), folinic acid, fluorouracil, oxaliplatin, and irinotecan (FOLFOXIRI), including ≤5 patients each.

**Treatment outcomes**

RECIST and CA19.9 response of metastatic patients receiving a first-line and a primary/neoadjuvant therapy as upfront treatment within one of the four largest chemotherapy regimen subgroups (n ≥ 9) is shown in Table 5.

Concerning survival outcomes of metastatic patients treated with first-line chemotherapy, median follow-up was 17.8 months (range 8.1-148.1 months). Median PFS (mPFS) of the (m)FOLFIRINOX/FOLFOXIRI subgroup (n = 16) was >12.9 months (not reached; range 4.8-24.3 months), with five (31%) patients who were progression free at 10.7-24.3 months (median 15 months). Conversely, all 17 patients treated with AG experienced disease progression, with an mPFS of 6.4 months (range 2.0-17.2 months). In the FOLFOX/GEMOX subgroup (n = 9) mPFS was 8.0 months (range 2.1-127.5 months), with only one (11%) patient progression free at 17.8 months. Lastly, the 11 patients receiving a four-drug cisplatin-based regimen (PAXG/PEXG) had an mPFS of 11.4 months (not reached; range 4.4-20 months), with two (18%) progression free at 10.8-12.7 months (median 11.7 months).

Median OS (mOS) of the 16 patients treated with (m)FOLFIRINOX/FOLFOXIRI was >17.3 months (not reached; range 7.1-84.7 months), with nine (56%) patients alive at the time of database lock, at 10.7-84.7 months (median 20.4 months). Median OS of the AG subgroup (n = 17) was 16.0 months (range 3.1-45.8 months), with three (18%) patients alive at 13.9-33.4 months (median 22.6 months). An mOS >10.5 months (not reached; range 8.5-148 months) was reported for the nine patients receiving FOLFOX/GEMOX, four (44%) of whom were alive at 8.5-148 months (median 12.2 months). Finally, the 11 patients treated with PAXG/PEXG had an mOS of >12.7
months (not reached; range 4.4-41 months), with five (45%) patients alive at 8.1-41 months (median 12.7 months).

The three remaining metastatic patients who received a first-line chemotherapy were treated either within a clinical trial with napabucasin plus nab-paclitaxel with gemcitabine ($n = 1$) or with gemcitabine ($n = 2$), all experiencing disease progression and death, with an mPFS of 3 months (range 1-5 months) and an mOS of 7.6 months (range 1.6-8.8).

In order to avoid the immortal time bias, we performed an additional outcome analysis, excluding those metastatic patients whose gBRCA testing was performed after first-line chemotherapy conclusion, likely due to favorable outcome. Four patients were then excluded [three treated with (m)FOLFIRINOX and one with GEMOX]. RECIST and CA19.9 responses of this second analysis are shown in Table 5. The (m)FOLFIRINOX/FOLFOXIRI subgroup encompassed 13 patients, who had an mPFS >12 months (not reached; range 12-30 months).

### Table 1. Patients and treatment characteristics

|                      | All patients ($n = 85$) | Toxicity cohort ($n = 74$) | Outcome cohort ($n = 83$) |
|----------------------|-------------------------|---------------------------|---------------------------|
| **Age at diagnosis (years), median (range)** | 60 (34-84) | 61 (34-84) | 61 (34-84) |
| **Sex, n (%)**       |                      |                           |                           |
| Female               | 46 (54)               | 39 (53)                   | 44 (53)                   |
| Male                 | 39 (46)               | 35 (47)                   | 39 (47)                   |
| **ECOG PS at diagnosis, n (%)** |              |                           |                           |
| 0                    | 57 (67)               | 47 (63)                   | 55 (66)                   |
| 1                    | 24 (28)               | 23 (31)                   | 24 (29)                   |
| 2                    | 4 (5)                 | 4 (6)                     | 4 (5)                     |
| **Clinical stage at diagnosis, n (%)** |             |                           |                           |
| I                    | 7 (8)                 | 5 (7)                     | 7 (8)                     |
| II                   | 11 (13)               | 10 (13)                   | 10 (12)                   |
| III                  | 10 (12)               | 9 (12)                    | 10 (12)                   |
| IV                   | 57 (67)               | 50 (68)                   | 56 (68)                   |
| **T site, n (%)**    |                       |                           |                           |
| Head/uncinate        | 40 (49)               | 33 (47)                   | 39 (49)                   |
| Body                 | 23 (29)               | 19 (27)                   | 23 (29)                   |
| Tail                 | 14 (17)               | 14 (20)                   | 14 (18)                   |
| Diffuse              | 4 (5)                 | 4 (6)                     | 3 (4)                     |
| NA                   | 4                     | 4                         | 4                         |
| **Grading, n (%)**   |                       |                           |                           |
| 1                    | 3 (8)                 | 3 (8)                     | 3 (8)                     |
| 2                    | 20 (51)               | 18 (49)                   | 19 (50)                   |
| 3                    | 16 (41)               | 16 (43)                   | 16 (42)                   |
| NA                   | 46                    | 37                       | 45                       |
| **Liver metastases at diagnosis, n (%)** |             |                           |                           |
| Yes                  | 45 (79)               | 39 (78)                   | 44 (79)                   |
| No                   | 12 (21)               | 11 (22)                   | 12 (21)                   |
| **Baseline CA19.9, n (%)** |             |                           |                           |
| 0-37 U/ml            | 15 (21)               | 14 (21)                   | 15 (22)                   |
| >37 U/ml             | 56 (79)               | 51 (79)                   | 54 (78)                   |
| **Baseline CA19.9 U/ml, median (range)** | 1077 (37.6-456 308) | 956 (37.6-456 308) | 1315 (37.6-456 308) |
| **gBRCApv status, n (%)** |                     |                           |                           |
| gBRCA1               | 21 (25)               | 18 (24)                   | 21 (25)                   |
| gBRCA2               | 62 (73)               | 55 (74)                   | 60 (72)                   |
| gBRCA1 + gBRCA2      | 2 (2)                 | 1 (2)                     | 2 (3)                     |
| **Type of first chemotherapy, n (%)** |                     |                           |                           |
| Adjuvant             | 10 (12)               | 8 (11)                    | 10 (12)                   |
| Primary/neoadjuvant  | 18 (21)               | 16 (21)                   | 17 (20)                   |
| First line (metastatic) | 57 (67)     | 50 (68)                   | 56 (68)                   |
| **Regimen of first chemotherapy, n (%)** |                     |                           |                           |
| AG                   | 20 (24)               | 18 (24)                   | 20 (24)                   |
| (m)FOLFIRINOX/FOLFOXIRI | 30 (35)     | 26 (35)                   | 29 (35)                   |
| PAXG                 | 13 (15)               | 12 (16)                   | 12 (14)                   |
| GEMOX                | 5 (6)                 | 5 (7)                     | 5 (6)                     |
| Gemcitabine          | 5 (6)                 | 4 (6)                     | 5 (6)                     |
| PEXG                 | 4 (5)                 | 4 (6)                     | 4 (5)                     |
| FOLFOX               | 5 (6)                 | 3 (4)                     | 5 (6)                     |
| Other                | 3 (3)                 | 2 (2)                     | 3 (4)                     |
| Platinum based       | 58 (68)               | 51 (69)                   | 56 (68)                   |
| Nonplatinum based    | 27 (32)               | 23 (31)                   | 27 (32)                   |

AG, nab-paclitaxel plus gemcitabine; CA19.9, carbohydrate antigen 19.9; ECOG PS, Eastern Cooperative Oncology Group performance status; FOLFOX, folinic acid, fluorouracil, and oxaliplatin; FOLFIRINOX, folinic acid, fluorouracil, irinotecan, and oxaliplatin; gBRCA, germline BRCA; GEMOX, gemcitabine plus oxaliplatin; (m)FOLFIRINOX, modified folinic acid, fluorouracil, irinotecan, and oxaliplatin; NA, not available; PAXG, cisplatin, nab-paclitaxel, capecitabine, and gemcitabine; PEXG, cisplatin, epirubicin, capecitabine, and gemcitabine; PS, performance status; pv, pathogenic variant; T, primary tumor.
−4.8 to 24.3 months), with 6 (46%) patients who were progression free at 10.7-24.3 months (median 14.2 months). Median OS was >15 months (not reached; range 7.1-37.4 months), with eight (62%) patients alive at 10.7-37.4 months (median 18.7 months). In the FOLFOX/GEMOX subgroup (n = 8) mPFS was 7.2 months (range 2.1-17.8 months), with still only one (12%) patient progression free at 17.8 months. Median OS was >10.4 months (not reached; range 7.4-13.8 months) and three (37%) patients were alive at 8.5-13.8 months (median 10.5 months). In this additional analysis, we also compared outcomes of metastatic patients with gBRCA2pv (n = 11) versus gBRCA1pv (n = 38) treated with multidrug chemotherapy regimens (patients receiving single-agent chemotherapy were excluded). mPFS was 9.4 (range 2.4-6) versus 5.9 (range 0.9-14.2) months for the gBRCA2pv versus gBRCA1pv cohorts, with four (10%) patients progression free at 12.7-24.3 months (median 14.9 months) and two (18%) patients progression free at 10.7 months, respectively. Median OS was >14.1 months (not reached; range 3.1-47.9 months), with 15 (37%) patients alive at 8.1-41 months (median 20.4 months) in the gBRCA2pv subgroup, as opposed to >10.8 months (not reached; range 1.6-37.2 months), with three (27%) patients alive at 10.7-12.9 months (median 10.8 months) in the gBRCA1pv subgroup.

Outcome for patients receiving a primary/neoadjuvant upfront treatment (n = 17) is summarized in Table 5. Of note, 87% (13/15) of patients treated with platinum-based primary/neoadjuvant chemotherapy [(m)FOLFIRINOX = 8, PAXG = 3, PEXG = 1, liposomal irinotecan (nal-IRI) plus folinic acid, fluouracil, oxaliplatin = 1], as opposed to none of the two patients receiving AG, were surgically resected.

The adjuvant chemotherapy subgroup included only 10 patients, treated with heterogeneous regimens [4 (m)FOLFIRINOX, 3 gemcitabine, 1 PEXG, 1 gemcitabine plus capcitabine, 1 AG]. DFS of the entire group was >16.8 months (not reached; range 8.9-87 months), with four (40%) patients who were disease free at 13.9-87 months (median 78.4 months), whereas OS was >50.4 months (not reached; range 13.9-90.1 months), with seven (70%) patients alive at 13.9-90.1 months (median 44.7 months).

**Table 2. Patients and treatment characteristics of the 53 metastatic patients assessed for outcome**

| Age at diagnosis (years), median (range) | AG (n = 17) | (m)FOLFIRINOX/FOLFOXIRI (n = 16) | FOLFOX/GEMOX (n = 9) | PAXG/PEXG (n = 11) |
|-----------------------------------------|-------------|---------------------------------|----------------------|---------------------|
| Sex, n (%)                              |             |                                 |                      |                     |
| Female                                  | 11 (65)     | 7 (44)                          | 5 (56)               | 4 (37)              |
| Male                                    | 6 (35)      | 9 (56)                          | 4 (44)               | 7 (63)              |
| ECOG PS at diagnosis, n (%)             |             |                                 |                      |                     |
| 0                                       | 13 (76)     | 12 (75)                         | 3 (33)               | 5 (45)              |
| 1                                       | 13 (76)     | 12 (75)                         | 3 (33)               | 5 (45)              |
| 2                                       | 1 (6)       | 0                               | 2 (22)               | 0                   |
| T site, n (%)                           |             |                                 |                      |                     |
| Head/uncinate                           | 8 (47)      | 6 (37)                          | 4 (50)               | 4 (37)              |
| Body                                    | 5 (29)      | 6 (37)                          | 2 (25)               | 2 (18)              |
| Tail                                    | 3 (18)      | 4 (26)                          | 2 (25)               | 5 (45)              |
| Diffuse                                 | 1 (6)       | 0                               | 0                    | 0                   |
| NA                                      | 0           | 0                               | 1                    | 0                   |
| Liver metastases at diagnosis, n (%)    |             |                                 |                      |                     |
| Yes                                     | 13 (77)     | 12 (75)                         | 6 (67)               | 10 (91)             |
| No                                      | 4 (23)      | 4 (25)                          | 3 (33)               | 1 (9)               |
| Baseline CA19.9, n (%)                  |             |                                 |                      |                     |
| 0-37 U/ml                               | 1 (6)       | 4 (29)                          | 2 (25)               | 2 (18)              |
| >37 U/ml                                | 15 (94)     | 10 (71)                         | 6 (75)               | 9 (82)              |
| NA                                      | 1           | 2                               | 1                    | 0                   |
| Baseline CA19.9 U/ml, median (range)    |             | 956 (130-8485)                  | 2850 (229-4518)      | 4099 (80-12 150)    | 2788 (65-456 308) |
| gBRCA1 status, n (%)                    |             |                                 |                      |                     |
| gBRCA1                                  | 3 (18)      | 4 (25)                          | 3 (33)               | 2 (18)              |
| gBRCA2                                  | 14 (82)     | 12 (75)                         | 5 (56)               | 9 (82)              |
| gBRCA 1 + 2                             | 0           | 0                               | 1 (11)               | 0                   |

AG, nab-paclitaxel plus gemcitabine; CA19.9, carbohydrate antigen 19.9; ECOG PS, Eastern Cooperative Oncology Group performance status; FOLFOX, folinic acid, fluorouracil, and oxaliplatin; FOLFOXIRI, folinic acid, fluorouracil, oxaliplatin, and irinotecan; gBRCA, germline BRCA; GEMOX, gemcitabine plus oxaliplatin; (m)FOLFIRINOX, [modified] folinic acid, fluorouracil, irinotecan, and oxaliplatin; NA, not available; PAXG, cisplatin, nab-paclitaxel, capecitabine, and gemcitabine; PEXG, cisplatin, epirubicin, capecitabine, and gemcitabine; PS, performance status; pv, pathogenic variant; T, primary tumor.

**Subsequent therapies**

By the time of database lock, 82% (9/11) of metastatic patients treated with first-line (m)FOLFIRINOX/FOLFOXIRI who experienced progression of disease had started and/or completed a second-line treatment, mostly gemcitabine based (7/9, 78%). Among the 17 patients treated with first-line AG who had disease progression, 14 (82%) had started and/or completed a second-line chemotherapy, receiving a platinum-based combination in most cases (12/14, 86%). Patients treated upfront with an oxaliplatin-doublet (FOLFOX/GEMOX) received a second-line treatment in 75% of cases with disease progression (6/8), with heterogeneous regimens. Finally, the nine PAXG/PEXG patients who had progression of disease started and/or completed a
Treatment toxicity of the four most commonly used (\(n \geq 9\)) chemotherapy regimens

| Regimen | Grade 1-2 | Grade 3 | Grade 4 |
|---------|-----------|---------|---------|
| AG \((n = 18)\) | 4 (27) | 6 (40) | 1 (7) |
| Neutropenia, n (%) | 7 (39) | 7 (39) | 0 (0) |
| Anemia, n (%) | 12 (67) | 2 (11) | 0 (0) |
| Thrombocytopenia, n (%) | 10 (55) | 0 (0) | 0 (0) |
| Febrile neutropenia, n (%) | 0 (0) | 1 (5) | 0 (0) |
| Fatigue, n (%) | 14 (77) | 1 (5) | 0 (0) |
| Nausea, n (%) | 4 (22) | 1 (5) | 0 (0) |
| Vomiting, n (%) | 4 (22) | 1 (5) | 0 (0) |
| Diarrhea, n (%) | 3 (14) | 0 (0) | 0 (0) |
| Constipation, n (%) | 2 (11) | 0 (0) | 0 (0) |
| Mucositis, n (%) | 4 (22) | 1 (5) | 0 (0) |
| HFS, n (%) | 1 (5) | 0 (0) | 0 (0) |
| Fever, n (%) | 3 (17) | 1 (5) | 0 (0) |
| Infections, n (%) | 2 (11) | 0 (0) | 0 (0) |
| CIPN, n (%) | 6 (33) | 1 (5) | 0 (0) |
| Peripheral edema, n (%) | 2 (11) | 0 (0) | 0 (0) |
| Rash/allergy, n (%) | 1 (5) | 0 (0) | 0 (0) |

mFOLFIRINOX: modified FOLFIRINOX; PAXG, cisplatin, nab-paclitaxel, capecitabine, and gemcitabine.

One patient treated with FOLFOXIRI regimen was excluded.

We believe that our data highlighted a potentially increased toxicity on proliferating cells, alongside an apparently enhanced activity of platinum-based regimens compared with platinum-free regimens.

Toxicity profile varied across chemotherapy regimens and we acknowledge that the limited sample size of our series hampers drawing firm conclusions on this topic, particularly on rare adverse events whose rates may consistently vary due to a single supplementary or decremental episode. In addition, under reporting of adverse events, mostly those that are either low grade or unrelated to laboratory data, is an inherent weakness of retrospective analyses and may account for the discrepancies between nonhematological toxicities rates reported in our survey and those described in the literature. However, these limitations are likely less stringent in the case of grade 3-4 adverse events that we have considered for this analysis, and focusing on more frequent toxicities, such as neutropenia, may temperate these drawbacks. Furthermore, another strength of our series is the availability of data on dose intensity and treatment duration of the different regimens, paving the way for a more suitable interpretation of toxicity data that may provide hypothesis-generating information. In the AG platinum-free regimen, the median relative dose intensity was comparable to the pivotal phase III MPACT trial, being unchanged for gemcitabine and slightly reduced for nab-paclitaxel (72% versus 81%). Consistently, neutropenia rate (39% versus 38%) and anemia (11% versus 13%) were superimposable, while a minor reduction of grade 3-4 fatigue, chemotherapy-induced peripheral neuropathy (CIPN; 5% versus 17% for both events), and thrombocytopenia (0% versus 13%) was observed. With regard to oxaliplatin-containing regimens, data on patients treated with mFOLFIRINOX are difficult to interpret in the context of prior literature due to the different populations (mainly metastatic versus adjuvant), lack of information on granulocyte.

Table 4. Treatment dose intensity and median number of cycles of the four most commonly used (\(n \geq 9\)) chemotherapy regimens

| Regimen | Dose intensity (%) | Number of cycles, median (range) |
|---------|--------------------|---------------------------------|
| AG \((n = 18)\) | | 7 (2-10) |
| Nab-paclitaxel | 72 | |
| Gemcitabine | 76 | |
| FOLFIRINOX \((n = 15)\) | | 8 (4-21) |
| Oxaliplatin | 64 | |
| Irinotecan | 58 | |
| Fluorouracil bolus | 35 | |
| Fluorouracil c.i. | 63 | |
| mFOLFIRINOX \((n = 10)\) | | 10 (1-12) |
| Oxaliplatin | 85 | |
| Irinotecan | 79 | |
| Fluorouracil c.i. | 87 | |
| PAXG \((n = 12)\) | | 5.5 (1-6) |
| Cisplatin | 75 | |
| Nab-paclitaxel | 73 | |
| Capecitabine | 73 | |
| Gemcitabine | 65 | |

AG, nab-paclitaxel plus gemcitabine; c.i., continuous infusion; FOLFIRINOX, folinic acid, fluorouracil, irinotecan, and oxaliplatin; FOLFOXIRI, folinic acid, fluorouracil, oxaliplatin, and irinotecan; HFS, hand-foot syndrome; mFOLFIRINOX, modified FOLFIRINOX; PAXG, cisplatin, nab-paclitaxel, capecitabine, and gemcitabine.

One patient treated with FOLFOXIRI regimen was excluded.

We believe that our data highlighted a potentially increased toxicity on proliferating cells, alongside an apparently enhanced activity of platinum-based regimens compared with platinum-free regimens.

Toxicity profile varied across chemotherapy regimens and we acknowledge that the limited sample size of our series hampers drawing firm conclusions on this topic, particularly on rare adverse events whose rates may consistently vary due to a single supplementary or decremental episode. In addition, under reporting of adverse events, mostly those that are either low grade or unrelated to laboratory data, is an inherent weakness of retrospective analyses and may account for the discrepancies between nonhematological toxicities rates reported in our survey and those described in the literature. However, these limitations are likely less stringent in the case of grade 3-4 adverse events that we have considered for this analysis, and focusing on more frequent toxicities, such as neutropenia, may temperate these drawbacks. Furthermore, another strength of our series is the availability of data on dose intensity and treatment duration of the different regimens, paving the way for a more suitable interpretation of toxicity data that may provide hypothesis-generating information. In the AG platinum-free regimen, the median relative dose intensity was comparable to the pivotal phase III MPACT trial, being unchanged for gemcitabine and slightly reduced for nab-paclitaxel (72% versus 81%). Consistently, neutropenia rate (39% versus 38%) and anemia (11% versus 13%) were superimposable, while a minor reduction of grade 3-4 fatigue, chemotherapy-induced peripheral neuropathy (CIPN; 5% versus 17% for both events), and thrombocytopenia (0% versus 13%) was observed. With regard to oxaliplatin-containing regimens, data on patients treated with mFOLFIRINOX are difficult to interpret in the context of prior literature due to the different populations (mainly metastatic versus adjuvant), lack of information on granulocyte.

second-line therapy in six cases (67%), three receiving GEMOX and three fluoropyrimidine plus irinotecan.

Considering the whole cohort of metastatic patients treated with first-line chemotherapy \((n = 57)\), 23 (40%) received olaparib throughout their course of treatment.

DISCUSSION

This multicenter survey provides an extensive overview of the impact of chemotherapy combinations that are commonly used for PDAC treatment in clinical practice, focusing on toxicity, dose intensity, and outcome in a large series of patients harboring gBRCA1-2pv.
colony-stimulating factors used in our series, and lack of
dose-intensity information in the phase III trial.29 By
contrast, patients treated with FOLFIRINOX received a me-
dian of only 8 cycles as opposed to 10 in the phase III trial28
and also the dose intensity of 5-FU, irinotecan, and oxali-
platin (64%, 58%, and 63%, respectively) was considerably
lower (82%, 81%, and 78%, respectively).28 Despite the
substantial reduction in chemotherapy total dose, grade 3-4
neutropenia rate (47%) in our series overlapped with pre-
viously reported data (46%).28 Further grade 3-4 toxicities,
such as thrombocytopenia, anemia, fatigue, diarrhea,
vomiting, and CIPN, did not occur. However, these events
usually occur later than neutropenia in the course of
treatment and the lower rates observed may be a conse-
quence of early dose reduction. Consistent with this inter-
pretation, the cisplatin-based PAXG regimen, which was
administered for an overlapping number of cycles and with
comparable dose intensity with respect to the randomized
phase II trial, paid the toll of an increased grade 3-4 neu-
tropenia (66% versus 41%), thrombocytopenia (17% versus
7%), and diarrhea (25% versus 7%).30 Noteworthy, toxicities
that are multifactorial or less related to proliferating cells,
such as anemia, fatigue, and CIPN, overlapped the previ-
ously reported rates.30
Other retrospective investigations including 31-150 pa-
tients addressed chemotherapy toxicity in other types of
gBRCA1-2pv neoplasms.19,26-39 Albeit mostly not report-
ing information on dose-intensity or treatment duration,
these series apparently confirm our findings. Patients with
breast cancer receiving anthracycline- and taxane-based
chemotherapy had no difference in toxicity as opposed to
wild-type patients.24,25,36,37 Only acute (i.e. after the first

### Table 5. RECIST and CA19.9 response of metastatic PDAC patients receiving a first-line or a primary/neoadjuvant upfront treatment within one of the four largest chemotherapy regimen subgroups (n ≥ 9)

|                      | First line (I L) | Primary/neoadjuvant (P/N) | All (I L + P/N) |
|----------------------|------------------|---------------------------|----------------|
| RECIST response, n (%) |                  |                           |                |
| CR                   | 2 (12)           | 0 (0)                     | 2 (8)          |
| PR                   | 11 (69)          | 8 (89)                    | 19 (76)        |
| SD                   | 3 (19)           | 1 (11)                    | 4 (16)         |
| PD                   | 0 (0)            | 0 (0)                     | 0 (0)          |
| CA19.9 reduction at nadir, n (%) | 6 (67) | 2 (33) | 8 (53) |
| >89%                 | 3 (33)           | 4 (67)                    | 7 (47)         |
| Median time to CA19.9 nadir, (range), months | 4 (3-7) | 3 (2-4) | 3.6 (2-7) |
| AG                   |                  |                           |                |
| RECIST response, n (%) |                  |                           |                |
| CR                   | 0 (0)            | 0 (0)                     | 0 (0)          |
| PR                   | 7 (41)           | 1 (50)                    | 8 (42)         |
| SD                   | 6 (35)           | 1 (50)                    | 7 (37)         |
| PD                   | 4 (24)           | 0 (0)                     | 4 (21)         |
| CA19.9 reduction at nadir, n (%) | 5 (45) | 1 (50) | 6 (46) |
| >89%                 | 6 (55)           | 1 (50)                    | 7 (54)         |
| Median time to CA19.9 nadir, (range), months | 3 (1.5-8) | 5 (2-8) | 3 (1.5-8) |
| FOLFOX/GEMOX         | n = 9            | n = 1                     | n = 10         |
| RECIST RESPONSE, n (%) |                  |                           |                |
| CR                   | 0 (0)            | 0 (0)                     | 0 (0)          |
| PR                   | 5 (56)           | 1 (100)                   | 6 (60)         |
| SD                   | 1 (11)           | 0 (0)                     | 1 (10)         |
| PD                   | 3 (33)           | 0 (0)                     | 3 (30)         |
| CA19.9 reduction at nadir, n (%) | 1 (33) | 0 (0) | 1 (25) |
| >89%                 | 2 (67)           | 1 (100)                   | 3 (75)         |
| Median time to CA19.9 nadir, (range), months | 5 (2-5) | 3 | 4 (2-5) |
| PAXG/PEXG            | n = 11           | n = 4                     | n = 15         |
| RECIST response, n (%) |                  |                           |                |
| CR                   | 1 (9)            | 0 (0)                     | 1 (7)          |
| PR                   | 7 (64)           | 2 (50)                    | 9 (60)         |
| SD                   | 3 (27)           | 2 (50)                    | 5 (33)         |
| PD                   | 0 (0)            | 0 (0)                     | 0 (0)          |
| CA19.9 reduction at nadir, n (%) | 6 (67) | 2 (67) | 8 (67) |
| >89%                 | 3 (33)           | 1 (33)                    | 4 (33)         |
| Median time to CA19.9 nadir, (range), months | 4.5 (1.7-7) | 5 (5-6) | 5 (1.7-7) |

AG, nab-paclitaxel plus gemcitabine; CA19.9, carbohydrate antigen 19.9; CR, complete response; FOLFOX, folinic acid, fluorouracil, and oxaliplatin; FOLFIRINOX, folinic acid, fluorouracil, oxaliplatin, and irinotecan; GEMOX, gemcitabine plus oxaliplatin; (m)FOLFIRINOX, (modified) folinic acid, fluorouracil, irinotecan, and oxaliplatin; PANG, cisplatin, nab-
paclitaxel, capcitabine, and gemcitabine; PD, progressive disease; PDAC, pancreatic ductal adenocarcinoma; PEXG, cisplatin, epirubicin, capcitabine, and gemcitabine; PR, partial response; SD, stable disease.

a,b Additional outcome analysis: a(FOLFIRINOX/FOLFIRINOX n = 13; RECIST response, n (%); CR, 1 (8); PR, 9 (69); SD, 3 (23); PD, 0; CA19.9 reduction at nadir, n (%); n = 8; >50%, 7 (87); <50%, 1 (13); median time to CA19.9 nadir (range): 4.2 (3-7) months. bFOLFOX/GEMOX n = 8 RECIST response, n (%); CR, 0; PR, 4 (50); SD, 1 (12); PD, 3 (38). CA19.9 reduction at nadir (n (%); n = 2; >50%, 1 (50); <50%, 1 (50); median time to CA19.9 nadir (range): 3.5 (2-5) months.

One patient received liposomal irinotecan (nal-IRI) plus folinic acid, fluorouracil, oxaliplatin with PR. CA19.9 was not expressed.
cycle) neutropenia increased without any impact on overall grade 3-4 maximum toxicity.24,36 By contrast, in patients with ovarian cancer receiving platinum-based chemotherapy, hematological toxicity was more serious among those harboring gBRCA1-2pv in the majority of series, 26,28 with a few exceptions in smaller surveys23 or without separately reported data for patients receiving either intravenous or intraperitoneal platinum salts.39

The unique data about chemotherapy toxicity in PDAC patients with gBRCA1-2pv can be derived from the phase II trial by O’Reilly and colleagues,21 which investigated the activity of gemcitabine plus cisplatin with or without veliparib in patients with gBRCA1-2 or PALB2pv.21 In the 23 patients treated with gemcitabine plus cisplatin, grade 3-4 neutropenia and anemia were 30% and 35%, respectively.21 Again, these rates are higher than expected on the basis of a previous phase III trial with gemcitabine plus cisplatin in unselected PDAC patients (25% and 5%, respectively), when data are properly interpreted in the context of the mean planned weekly dose of gemcitabine that was nearly halved (400 mg/mq/week versus 750 mg/mq/week).40

Regarding the response rate and survival endpoints of our survey, the descriptive analysis was mainly focused on the larger group of metastatic PDAC patients. RECIST complete and partial responses were numerically higher with the three- (81%) or four-drug (73%) platinum-containing regimens that outperformed AG (41%) and oxaliplatin-based doublets (56%). Consistently, CA19.9 reduction at nadir >89% was reported in two-third of metastatic patients treated with triplets and quadruplet, as opposed to 33% and 45% of patients receiving oxaliplatin-based doublets or AG, respectively. Keeping in mind the limitations of the small sample size of any treatment subgroup and the retrospective nature of our analysis, RECIST and CA19.9 response rates were 23%-49% higher than expected based on the literature with platinum salt-based doublets or AG, respectively. Keeping in mind the limitations of the small sample size of any treatment subgroup and the retrospective nature of our analysis, RECIST and CA19.9 response rates were 23%-49% higher than expected based on the literature with platinum salt-based doublets or AG, respectively. Keeping in mind the limitations of the small sample size of any treatment subgroup and the retrospective nature of our analysis, RECIST and CA19.9 response rates were 23%-49% higher than expected based on the literature with platinum salt-based doublets or AG, respectively. Keeping in mind the limitations of the small sample size of any treatment subgroup and the retrospective nature of our analysis, RECIST and CA19.9 response rates were 23%-49% higher than expected based on the literature with platinum salt-based doublets or AG, respectively.

In conclusion, albeit caution should be exercised due to drawbacks of this analysis, including the lack of a matching internal cohort of wild-type controls, extensive gBRCA testing is recommended in all PDAC patients, irrespective of stage, to inform and drive the therapeutic choice, which should favor platinum-based triplets and quadruplets whenever a gBRCA1-2pv is detected.

ACKNOWLEDGEMENTS
None.

FUNDING
This study was partially supported by MyEverest ONLUS (no grant number) and by Fondazione Italiana Malattie Pancreas (FIMP, Ministero Salute, [grant number CUP_J33G13000210001]).

DISCLOSURE
MN reports travel expenses from Celgene; speaker honorarium from Accademia della Medicina; and consultant honoraria from EMD Serono. IG serves on the advisory board of Amgen, Takeda, and Eisai. GT reports travel expenses and personal honoraria for advisory boards from Celgene, Merck, AstraZeneca, Servier, and BMS. SC reports travel expenses and personal honoraria for the following companies: Amgen, Bayer, Eli Lilly, and Servier (as speaker); Amgen, Eli Lilly, Bayer, Baxter, Merck Sharp & Dohme (MSD), Servier (on advisory boards). Amgen, Baxter, Eli Lilly, Celgene, Novartis, and MSD (as consultant); receiving research grant from Celgene and Eisai. MM reports personal

with platinum salt-containing triplets or quadruplets (excluded those whose gBRCA testing was performed after first-line chemotherapy conclusion; data not shown).

National Comprehensive Cancer Network (NCCN) guidelines suggest that all newly diagnosed PDAC patients meet the criteria for genetic testing, regardless of age at diagnosis, family history, or tumor stage.45 Indeed, our data suggest that the identification of a gBRCA1-2pv has a relevant impact not only on screening of patient’s relatives and of other gBRCA1-2-related neoplasms but also on therapeutic decisions.

Conclusion
Overall, our findings endorse the hypothesis that BRCA1-2 haploinsufficiency, namely, mutation of a single allele, might result in increased cytotoxic effect of DNA cross-linking agents, such as platinum salts, on both cancer cells and proliferating noncancerous cell types (e.g. hematopoietic and bowel cells). Consequently, dose reductions, treatments delays, and higher risk of (hematological and gastrointestinal) toxicity encumber administration of platinum-based chemotherapy regimens. Nevertheless, this perspective efficacy is clearly superior, when compared with platinum-free therapeutic options, and low-dose cisplatin-containing regimens or oxaliplatin-containing triplets with appropriate dose reductions have manageable toxicity and must be preferred.

In conclusion, albeit caution should be exercised due to drawbacks of this analysis, including the lack of a matching internal cohort of wild-type controls, extensive gBRCA testing is recommended in all PDAC patients, irrespective of stage, to inform and drive the therapeutic choice, which should favor platinum-based triplets and quadruplets whenever a gBRCA1-2pv is detected.

ACKNOWLEDGEMENTS
None.

FUNDING
This study was partially supported by MyEverest ONLUS (no grant number) and by Fondazione Italiana Malattie Pancreas (FIMP, Ministero Salute, [grant number CUP_J33G13000210001]).

DISCLOSURE
MN reports travel expenses from Celgene; speaker honorarium from Accademia della Medicina; and consultant honoraria from EMD Serono. IG serves on the advisory board of Amgen, Takeda, and Eisai. GT reports travel expenses and personal honoraria for advisory boards from Celgene, Merck, AstraZeneca, Servier, and BMS. SC reports travel expenses and personal honoraria for the following companies: Amgen, Bayer, Eli Lilly, and Servier (as speaker); Amgen, Eli Lilly, Bayer, Baxter, Merck Sharp & Dohme (MSD), Servier (on advisory boards). Amgen, Baxter, Eli Lilly, Celgene, Novartis, and MSD (as consultant); receiving research grant from Celgene and Eisai. MM reports personal
honorary as speaker or consultant for the following companies: AstraZeneca, MSD, Boehringer Ingelheim, Pfizer, EUSA Pharma, Merck-Serono, Novartis, Roche, Ipsen, and Mylan. MR reports travel expenses and personal honorary for advisory boards from Celgene, Merck, AstraZeneca, Baxalta (2016), Baxter, Sanofi (2017), Servier, Shire, Eli Lilly, Pfizer (2016), Novocure (2016), and Novartis (2016); personal honorary for steering committee work for AstraZeneca, and nonremunerated steering committee activities for Boston Pharmaceuticals. All other authors have declared no conflicts of interest.

DATA SHARING
Data are available upon reasonable request.

REFERENCES

1. O’Connor MJ. Targeting the DNA damage response in cancer. Mol Cell. 2015;60(4):547-560.
2. Jasin M. Homologous repair of DNA damage and tumorigenesis: the BRCA connection. Oncogene. 2002;21(58):8981-8993.
3. Roy R, Chun J, Powell SN. BRCA1 and BRCA2: different roles in a common pathway of genome protection. Nat Rev Cancer. 2011;11(1):68-78.
4. Petrucelli N, Daly MB, Pal T. BRCA1- and BRCA2-associated hereditary breast and ovarian cancer. 1998 Sep 4 [updated 2016 Dec 15]. In: Adam MP, Ardinga HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Adam MP, eds. GeneReviews®. Seattle: University of Washington, Seattle. 1993-2020. Available at https://www.ncbi.nlm.nih.gov/books/NBK1247/. Accessed August 3, 2021.
5. Kennedy RD, Quinn JE, Mullan PB, Johnston PG, Harkin DP. The role of homologous recombination as a predictor of drug response. Nat Rev Cancer. 2010;10(6):405-415.
6. Dyrs T, Dent R, Blecharz P, et al. Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer. Breast Cancer Res. 2012;14(4):R110.
7. Tutt A, Tohey V, Cheang MCU, et al. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCaness subgroups: the TNT trial. N Engl J Med. 2018;378(25):2395-2406.
8. De Picciotto N, Cacheux W, Roth A, et al. Ovarian cancer: status of biomarker research. Mol Med Today. 2021;27(7):251-265.
9. De Picciotto N, Cacheux W, Roth A, et al. Ovarian cancer: status of biomarker research. Mol Med Today. 2021;27(7):251-265.
10. Litton JK, Rugo HS, Ettl J, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA2 Mutation. N Engl J Med. 2018;379:753-763.
11. Foo T, George A, Banerjee S. PARP inhibitors in ovarian cancer: an overview of the practice-changing trials. Genes Chromosomes Cancer. 2021;60(5):385-397.
12. Grigolo G, Dieci MV, Miglietta F, Guarneri V, Conte P. Olaparib for advanced breast cancer. Future Oncol. 2020;16(12):717-732.
13. Pilarski R. The role of BRCA testing in hereditary pancreatic and prostate cancer families. Am Soc Clin Oncol Educ Book. 2019;39:79-86.
14. Premath N, O’Reilly EM. BReast Cancer (BRCA) gene mutations as an emerging biomarker for the treatment of gastrointestinal malignancies. Chin Clin Oncol. 2020;9(5):64.
15. Khomiak A, Brunner M, Kordes M, et al. Recent discoveries of diagnostic, prognostic and predictive biomarkers for pancreatic cancer. Cancers (Basel). 2020;12(11):3234.
16. Holter S, Borgida A, Dodd A, et al. Germline BRCA mutations in a large clinic-based cohort of patients with pancreatic adenocarcinoma. J Clin Oncol. 2015;33(28):3124-3129.
17. Couch FJ, Johnson MR, Rabe KG, et al. The prevalence of BRCA2 mutations in familial pancreatic cancer. Cancer Epidemiol Biomarkers Prev. 2007;16(2):342-346.
18. Peretti U, Cavaliere A, Nger M, et al. Germlinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort. ESMO Open. 2021;6(1):100032.
19. Golan T, Kanji ZS, Epelbaum R, et al. Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers. Br J Cancer. 2014;111(6):1132-1138.
20. Rebelatto TF, Falavigna M, Pozzari M, et al. Should platinum-based chemotherapy be preferred for germline BRCA1 and BRCA2 (BRC1A and BRC2A) and 2-mutated pancreatic ductal adenocarcinoma (PDAC) patients? A systematic review and meta-analysis. Cancer Treat Rev. 2019;80:101895.
21. O’Reilly EM, Lee JW, Zalupski M, et al. Randomized, multicenter, phase II trial of gemcitabine and cisplatin with or without veliparib in patients with pancreas adenocarcinoma and a germline BRCA/PALB2 mutation. J Clin Oncol. 2020;38(13):1378-1388.
22. Golan T, Hammel P, Reni M, et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med. 2019;381(4):e1471-e1475.
23. Weitzner O, Yagur Y, Kadan Y, et al. Chemotherapy toxicity in BRCA mut mutation carriers undergoing first-line platinum-based chemotherapy. Oncologist. 2019;24(12):e1471-e1475.
24. Huszno J, Budryk M, Koloza Z, Nowara E. The influence of BRCA1/ BRCA2 mutations on toxicity related to chemotherapy and radiotherapy in early breast cancer patients. Oncology. 2013;85(5):278-282.
25. Drooger JC, Heemskerk-Gerritsen BAM, Smallenbroek N, Epskamp C, Seyneave CM, Seyneave CM. Toxicity of (neo)adjuvant chemotherapy for BRCA1- and BRCA2-associated breast cancer. Breast Cancer Res Treat. 2016;156(3):557-566.
26. Kotsopoulos J, Willows K, Trat S, et al. BRCA mutation status is not associated with increased hematoxicity toxicity among patients undergoing platinum-based chemotherapy for ovarian cancer. Int J Gynecol Cancer. 2018;28(1):69-76.
27. Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691-1703.
28. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817-1825.
29. Conroy T, Hammel P, Hebbard M, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018;379(25):2395-2406.
30. Reni M, Zanon S, Peretti U, et al. Nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in metastatic pancreatic adenocarci-noma (PACT-19): a randomised phase 2 trial. Lancet Gastroenterol Hepat. 2018;3(10):691-697.
31. Louvet C, Labianca R, Hammel P, et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCA phase III trial. J Clin Oncol. 2005;23(15):3509-3516.
32. Reni M, Balzano G, Zanon S, et al. Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2-3 trial. Lancet Gastroenterol Hepatol. 2018;3(6):413-423.
33. Gill S, Ko YJ, Cripps C, et al. PANCREOX: A randomized phase III study of fluorouracil/leucovorin with or without oxaliplatin for second-line advanced pancreatic cancer in patients who have received gemcitabine-based chemotherapy. J Clin Oncol. 2016;34(32):3914-3920.
34. Vivaldi C, Caparello C, Musettini G, et al. First-line treatment with FOLFIRINOX for advanced pancreatic cancer in clinical practice: patients’ outcome and analysis of prognostic factors. Int J Cancer. 2016;139(4):938-945.
35. Sonbol MB, Ahn DH, Goldstein D, et al. CanStem111P trial: a phase III study of nab-paclitaxel with gemcitabine. Future Oncol. 2019;15(12):1295-1302.
36. Friedlaender A, Vuilleumier A, Viassolo V, et al. BRCA1/BRCA2 germline mutations and chemotherapy-related hematological toxicity in breast cancer patients. Breast Cancer Res Treat. 2019;174(3):775-783.

37. Bayraktar S, Zhou JZ, Bassett R, et al. Clinical outcome and toxicity from taxanes in breast cancer patients with BRCA1 and BRCA2 pathogenic germline mutations. Breast J. 2020;26(8):1572-1582.

38. Tomao F, Musacchio L, Di Mauro F, et al. Is BRCA mutational status a predictor of platinum-based chemotherapy related hematologic toxicity in high-grade serous ovarian cancer patients? Gynecol Oncol. 2019;154(1):138-143.

39. Gillen J, Miller A, Bell-McGuinn KM, et al. Post hoc analyses of GOG 9923: does BRCA status affect toxicities?: an NRG oncology study. Gynecol Oncol. 2021;161:512-515.

40. Colucci G, Labianca R, Di Costanzo F, et al. Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study. J Clin Oncol. 2010;28(10):1645-1651.

41. Ghosn M, Farhat F, Kattan J, et al. FOLFOX-6 combination as the first-line treatment of locally advanced and/or metastatic pancreatic cancer. Am J Clin Oncol. 2007;30(1):15-20.

42. Tempero M, Oh DY, Tabernero J, et al. Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study. Ann Oncol. 2021;32:600-608.

43. Van Cutsem E, Tempero MA, Sigal D, et al. Randomized phase III trial of pegvorhyaluronidase alfa with nab-paclitaxel plus gemcitabine for patients with hyaluronan-high metastatic pancreatic adenocarcinoma. J Clin Oncol. 2020;38(27):3185-3194.

44. Wattenberg MM, Asch D, Yu S, et al. Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation. Br J Cancer. 2020;122(3):333-339.

45. National Comprehensive Cancer Network (NCCN). NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian and Pancreatic Cancer (Version 1.2021). Plymouth Meeting, PA: National Comprehensive Cancer Network (NCCN); 2020.